Certified by Founder Lodge
NUCLIDIUM AG
Switzerland - Basel, BS
START UP
1 Disclosed Funding Rounds $98,461,860
0 Participating Investments
-
Founded date
2017
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for ta
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 10 ,2025 | Series B | $98,461,860 |
Eurazeo
DeepTech & Climate Fonds
Wellington Partners
Bayern Kapital GmbH
NEVA SGR
Angelini Ventures
VIVES Partners
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
